BR112018073454A2 - vacinas - Google Patents

vacinas

Info

Publication number
BR112018073454A2
BR112018073454A2 BR112018073454A BR112018073454A BR112018073454A2 BR 112018073454 A2 BR112018073454 A2 BR 112018073454A2 BR 112018073454 A BR112018073454 A BR 112018073454A BR 112018073454 A BR112018073454 A BR 112018073454A BR 112018073454 A2 BR112018073454 A2 BR 112018073454A2
Authority
BR
Brazil
Prior art keywords
derived
fusion polypeptides
relates
pvcsp
plasmids
Prior art date
Application number
BR112018073454A
Other languages
English (en)
Inventor
Reyes-Sandoval Arturo
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of BR112018073454A2 publication Critical patent/BR112018073454A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção refere-se a partículas, particularmente partículas tipo vírus (vlps), compreendendo polipeptídeos de fusão compreendendo unidades de repetição selecionadas derivadas das regiões de repetição das proteínas circunsporozoítas tipo i e tipo ii (csp) de plasmodium vivax (pv), em conjunto com uma sequência de aminoácidos derivada da sequência de pvcsp c terminal. em algumas modalidades, o polipeptídeo de fusão compreende adicionalmente uma sequência de aminoácidos derivada da sequência de pvcsp n terminal e/ou um polipeptídeo de antígeno de superfície derivado do vírus da hepatite b (hbv-s). a invenção também se refere a sequências de nucleotídeos que codificam para tais polipeptídeos de fusão, vetores e plasmídeos compreendendo essas sequências de nucleotídeos, e células hospedeiras compreendendo tais vetores e plasmídeos. a invenção refere-se adicionalmente a composições, particularmente composições para vacinas, compreendendo os polipeptídeos de fusão ou vlps para uso como vacinas para a prevenção da malária.
BR112018073454A 2016-05-19 2017-05-18 vacinas BR112018073454A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1608821.3A GB201608821D0 (en) 2016-05-19 2016-05-19 Vaccines
PCT/GB2017/051391 WO2017199038A1 (en) 2016-05-19 2017-05-18 Vaccines

Publications (1)

Publication Number Publication Date
BR112018073454A2 true BR112018073454A2 (pt) 2019-08-27

Family

ID=56369630

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073454A BR112018073454A2 (pt) 2016-05-19 2017-05-18 vacinas

Country Status (6)

Country Link
US (2) US11197920B2 (pt)
EP (1) EP3458087A1 (pt)
BR (1) BR112018073454A2 (pt)
GB (1) GB201608821D0 (pt)
PH (1) PH12018502430A1 (pt)
WO (1) WO2017199038A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines
CN109200271B (zh) * 2018-11-14 2021-01-29 江南大学 一种蛋白质及其在调控巨噬细胞免疫功能方面的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US6399062B1 (en) 1990-11-06 2002-06-04 The United States Of America As Represented By The Secretary Of The Navy Murine monoclonal antibody protective against Plasmodium vivax malaria
US7790186B2 (en) * 2005-01-18 2010-09-07 The United States Of America As Represented By The Secretary Of The Army Plasmodium vivax hybrid circumsporozoite protein and vaccine
US7749519B2 (en) 2005-12-09 2010-07-06 Kim Lee Sim Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax
TW200819462A (en) 2006-07-18 2008-05-01 Glaxosmithkline Biolog Sa Vaccines for malaria
WO2008041050A1 (es) 2006-10-04 2008-04-10 Centro Internacional De Vacunas Vacuna contra la malaria, basada en fragmentos y combinaciones de fragmentos de la proteína cs de plasmodium vivax
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
EP2234637A2 (en) 2007-12-21 2010-10-06 GlaxoSmithKline Biologicals S.A. Vaccines for malaria
JP2011507817A (ja) 2007-12-24 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
EP2945649B1 (en) 2013-01-22 2018-12-12 Oxford University Innovation Limited Composition and uses thereof
GB201416773D0 (en) 2014-09-23 2014-11-05 Glaxosmithkline Biolog S A And Chancellor Masters And Scolars Of The The University Of Oxford Novel Methods For Including An Imune Response
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines

Also Published As

Publication number Publication date
WO2017199038A1 (en) 2017-11-23
GB201608821D0 (en) 2016-07-06
US20220168409A1 (en) 2022-06-02
EP3458087A1 (en) 2019-03-27
US11197920B2 (en) 2021-12-14
PH12018502430A1 (en) 2019-03-18
US11944674B2 (en) 2024-04-02
US20190201515A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
MX340735B (es) Proteinas multimericas recombinantes de la influenza.
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
AR089039A1 (es) Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos
CO6150189A2 (es) Vacunas para malaria
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
ES2723273T3 (es) Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos
MX2021015465A (es) Vacuna para fiebre porcina africana.
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
PH12015500308A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
JP2015524422A5 (pt)
WO2015052543A3 (en) Malaria vaccination
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
BR112018073454A2 (pt) vacinas
IN2015DN03070A (pt)
EA201990719A1 (ru) Новые промоторы
BR112018003580A2 (pt) molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante
MX2019007924A (es) Vacunas contra la influenza.
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]